Transplantation, Consolidation and Maintenance
Autologous stem cell transplantation (ASCT) remains the standard of care option for those patients with newly-diagnosed multiple myeloma (MM) who are eligible for and able to tolerate… read more.
Autologous stem cell transplantation (ASCT) remains the standard of care option for those patients with newly-diagnosed multiple myeloma (MM) who are eligible for and able to tolerate… read more.
The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.
By Maria Dalby (article) and Esther Drain (interviews) Even in an era of rapid progress in terms of new agents and treatment approaches, stem cell transplantation (SCT) continues… read more.
Even in the era of novel therapies for newly-diagnosed and relapsed/refractory MM, there is a group of patients for whom the myeloma biology significantly shortens life expectancy. Allogeneic… read more.
Risk of living donor transplants can be mitigated by Thomas R. Collins Making living donor transplants less risky through new and innovative approaches is the best way to… read more.
Done correctly, living donation success is possible by Thomas R. Collins Life expectancy and quality of life measures tend to be quite high among live liver donors, generally… read more.
Done correctly, living donation success is possible by Thomas R. Collins Life expectancy and quality of life measures tend to be quite high among live liver donors, generally… read more.
Allogeneic stem cell transplantation: still a role in CLL/lymphoma? by Christine Clark Professor Peter Dreger, Heidelberg University Hospital, Germany. The goal of allogeneic transplant therapy is to provide… read more.
by Maria Dalby: Organ donation from children aged less than 2 years is extremely rare in the UK but could offer significant scope for expanding the donor pool…. read more.